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OBJECTIVE — To determine the efﬁcacy and safety of liraglutide (a glucagon-like peptide-1
receptor agonist) when added to metformin and rosiglitazone in type 2 diabetes.
RESEARCH DESIGN AND METHODS — This 26-week, double-blind, placebo-
controlled, parallel-group trial randomized 533 subjects (1:1:1) to once-daily liraglutide (1.2 or
1.8mg)orliraglutideplaceboincombinationwithmetformin(1gtwicedaily)androsiglitazone
(4 mg twice daily). Subjects had type 2 diabetes, A1C 7–11% (previous oral antidiabetes drug
[OAD] monotherapy 3 months) or 7–10% (previous OAD combination therapy 3 months),
and BMI 45 kg/m
2.
RESULTS — Mean A1C values decreased signiﬁcantly more in the liraglutide groups versus
placebo (mean  SE 1.5  0.1% for both 1.2 and 1.8 mg liraglutide and 0.5  0.1% for
placebo). Fasting plasma glucose decreased by 40, 44, and 8 mg/dl for 1.2 and 1.8 mg and
placebo, respectively, and 90-min postprandial glucose decreased by 47, 49, and 14 mg/dl,
respectively (P  0.001 for all liraglutide groups vs. placebo). Dose-dependent weight loss
occurredwith1.2and1.8mgliraglutide(1.00.3and2.00.3kg,respectively)(P0.0001)
compared with weight gain with placebo (0.6  0.3 kg). Systolic blood pressure decreased by
6.7, 5.6, and 1.1 mmHg with 1.2 and 1.8 mg liraglutide and placebo, respectively. Signiﬁcant
increases in C-peptide and homeostasis model assessment of -cell function and signiﬁcant
decreases in the proinsulin-to-insulin ratio occurred with liraglutide versus placebo. Minor
hypoglycemia occurred more frequently with liraglutide, but there was no major hypoglycemia.
Gastrointestinaladverseeventsweremorecommonwithliraglutide,butmostoccurredearlyand
were transient.
CONCLUSIONS — Liraglutide combined with metformin and a thiazolidinedione is a well-
tolerated combination therapy for type 2 diabetes, providing signiﬁcant improvements in gly-
cemic control.
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T
ype 2 diabetes is characterized by
insulin resistance and progressive
-cell failure. Treatment often must
beintensiﬁedovertime,usuallybyacom-
bination of agents that address both insu-
lin resistance and -cell dysfunction
(1,2). However, several available thera-
pies increase the risk for hypoglycemia
and weight gain, which may reduce pa-
tientadherenceandleadtopoorglycemic
control (3).
Glucagon-like peptide-1 (GLP-1) stim-
ulates insulin secretion and suppression of
glucagon secretion in a glucose-dependent
manner, delays gastric emptying, and de-
creases appetite (4). GLP-1 is rapidly de-
graded by dipeptidyl peptidase-4 (4).
Liraglutide is a human GLP-1 analog with
97% homology to native GLP-1 (5). Lira-
glutide has a half-life in humans of 13 h
compared with 1–2 min for native GLP-1,
making liraglutide suitable as a once-daily
treatment for patients with type 2 diabetes
(6).
In previously published phase 3 trials
(the Liraglutide Effect and Action in Dia-
betes [LEAD] Program), treatment with
liraglutide produced substantial and clin-
ically signiﬁcant reductions in A1C and
fasting and postprandial glucose (PPG)
levels, with a low risk of hypoglycemia,
and moderate weight loss (7–10). Lira-
glutidetreatmentaloneorincombination
withoralantidiabetesdrugs(OADs)dem-
onstrated signiﬁcantly larger A1C re-
ductions compared with glimepiride
(monotherapy)(7),rosiglitazone(incom-
bination with a sulfonylurea) (8), and in-
sulin glargine (in combination with
metformin and sulfonylurea) (10). When
initiatedasmonotherapyinasubgroupof
previously treatment-naïve patients with
type 2 diabetes, a mean A1C reduction of
1.6% was observed, with mean A1C val-
ues sustained below 7.0% over 52 weeks
(7). In combination with metformin, lira-
glutide reduced body weight by 2–3 kg,
with the majority of the weight loss being
fat (11). In addition, a decrease in systolic
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demonstrated (7–10). No major hypo-
glycemic events occurred during the ran-
domized treatment period when lira-
glutide was used as monotherapy or with
metformin (7,9). The current study in-
vestigated liraglutide treatment in com-
bination with metformin and a thiazo-
lidinedione (TZD) (rosiglitazone) as part
of the LEAD program. These three
glucose-lowering agents are of particu-
lar interest, as they have complementary
modes of action and are not generally
associated with increased risk of
hypoglycemia.
RESEARCH DESIGN AND
METHODS— Subjectswithtype2di-
abetes were screened and enrolled if they
were aged 18–80 years, had A1C be-
tween 7 and 11% (prestudy OAD mono-
therapy for 3 months) or 7–10%
(prestudy combination OAD therapy for
3 months), and had BMI 45 kg/m
2.
Subjectswhousedinsulinduringthepre-
vious 3 months (except short-term treat-
ment) were excluded. The protocol was
approved by local institutional review
boards, and subjects provided written in-
formed consent before the initiation of
any trial-related activities. The study was
conducted in accordance with the Decla-
rationofHelsinkiandGoodClinicalPrac-
tice Guidelines (12).
This 26-week, double-blind, random-
ized, placebo-control, parallel-group, mul-
ticenter (96 sites), two-country (U.S. and
Canada)trialrandomizedsubjects(1:1:1)
to receive 1.2 or 1.8 mg of once-daily li-
raglutide(NovoNordisk,Bagsværd,Den-
mark) or liraglutide placebo (Novo
Nordisk) injected subcutaneously by
subjects in combination with metformin
and rosiglitazone in all three treatment
groups.
Randomization was carried out using
a telephone- or Web-based randomiza-
tion system. Before randomization, eligi-
ble subjects underwent a 6- to 9-week
metformin and rosiglitazone run-in and
dose-titration period. Prior treatment
with OADs other than metformin and
rosiglitazone were discontinued. Subjects
previously treated with pioglitazone un-
derwent rosiglitazone titration (by trans-
ferring to the corresponding rosiglitazone
dose) or went directly to the maximum
dose if they were on the maximum piogli-
tazone dose. Metformin was started at
500mgatbreakfastandincreasedweekly
by increments of 500 mg to a ﬁnal dose of
2,000 mg/day (1,000 mg at breakfast and
at the evening meal). Rosiglitazone was
started at 4 mg in the morning and in-
creasedto8mg/day(4mginthemorning
andevening,thehighestapproveddosein
the U.S. and Canada). Subjects who tol-
erated the ﬁnal OAD doses and had fast-
ingplasmaglucose(FPG)values135–230
mg/dl (7.5–12.8 mmol/l) after 6 weeks’
treatment at the titrated doses were eligi-
ble for randomization. At randomization,
subjects initiated liraglutide or placebo
treatment with 100-l injections corre-
sponding to a 0.6-mg dose and increased
to 1.2 mg/day (200 l injections) after 1
week and then to 1.8 mg/day (300 l in-
jections) after an additional week for
those randomized to the highest dose. Li-
raglutide (active or placebo) was injected
subcutaneously once daily at any time of
the day in the upper arm, abdomen, or
thigh using a preﬁlled pen device. Sub-
jects were encouraged to use liraglutide
during the same overall time period. The
titration period was followed by a 24-
week maintenance period during which
the doses of study drugs were to be
maintained.
The primary outcome measure was
changeinA1Cfromrandomizationtothe
end of the study. Secondary end points
included changes in body weight; FPG;
seven-point plasma glucose proﬁles;
-cell function based on fasting insulin,
fasting C-peptide, and fasting proinsulin-
to-insulin ratio; the homeostasis model
assessment (HOMA) for -cell function
(HOMA-B) and insulin resistance
(HOMA-IR) (13); and lipids. Laboratory
analyses were performed by a central lab-
oratory (MDS Pharma Services in Canada
and Switzerland). A1C was assayed by a
method certiﬁed by the National Glyco-
hemoglobin Standardization Program.
Subjects were provided with MediSense
Precision Xtra/MediSense Optium glu-
cose meters (Abbott Laboratories, Abbott
Park, IL) calibrated to plasma glucose to
determine self-measured plasma glucose
(SMPG) and were asked to record values
in their diaries. The seven-point SMPG
proﬁle measurements were performed
before and 90 min after meals and at bed-
time for 2 consecutive days at weeks 0
(randomization),12,and26.Seruminsu-
lin and C-peptide values were determined
using a chemiluminescence immunoassay,
and proinsulin was measured in serum us-
ing an enzyme-linked immunosorbent
assay.
Safety variables included adverse
events, vital signs, electrocardiogram,
biochemical and hematology measures,
and subject-reported hypoglycemic epi-
sodes (plasma glucose 56 mg/dl
[3.1mmol/l]). A serious adverse event
was deﬁned as an adverse event that re-
sultedindeath,hospitalization,disability,
or a birth defect; was life threatening; or
required medical or surgical intervention
to prevent one of the other outcomes. Mi-
nor hypoglycemic episodes were deﬁned
as those that could be self-treated; major
episodes were deﬁned as requiring third-
party assistance or medical intervention.
Nausea was patient reported.
Statistical analysis
The analysis of efﬁcacy end points was
based on the intent-to-treat population,
deﬁned as subjects who were exposed to
at least one dose of trial product and had
one postbaseline measurement of the pa-
rameter. Each end point was analyzed us-
ing an ANCOVA model with treatment,
country, and previous antidiabetes treat-
ment as ﬁxed effects and baseline as the
covariate. Missing data were imputed as
thelastobservationcarriedforward.Sam-
ple size calculations were based on show-
ing A1C and body weight differences of
0.5 and 3%, respectively. The combined
power (calculated as the product of the
marginalpowersforA1Candweight)was
95%.
Superiority of glycemic control with
liraglutide versus comparators was con-
cluded if the upper limit of the two-sided
95% CI for the treatment difference in
change in A1C was 0%; equivalence
was also tested. The proportion of sub-
jectsachievingA1Ctargets(AmericanDi-
abetes Association [ADA] target: 7%;
AmericanAssociationofClinicalEndocri-
nologists [AACE]/International Diabetes
Federation [IDF] target: 6.5%) was
compared between treatments using a lo-
gistic regression model with treatment
and baseline A1C as covariates. CIs for
secondary end points were corrected us-
ing Dunnett’s test. Hypoglycemic epi-
sodeswereanalyzedusingagenerallinear
model including treatment as a ﬁxed ef-
fect. The signiﬁcance level was set at P 
0.05.
RESULTS— A total of 821 subjects
were enrolled in the study; 533 subjects
were randomly assigned to liraglutide or
placebo treatment after the metformin
plus rosiglitazone run-in period (288
subjects were run-in failures due to FPG
values out of range [135–230 mg/dl; 7.5–
12.8 mmol/l] or other reasons). Three
subjects were randomized but were with-
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Baseline characteristics were balanced
across treatment groups (Table 1). The
majority (83%) of the randomized sub-
jectsweretreatedwithtwoormoreOADs
before the study.
Efﬁcacy
At the end of the study, the mean A1C
values for the overall population de-
creased by (means  SE) 1.5  0.1% for
both 1.2 and 1.8 mg/day liraglutide
groups and 0.5  0.1% for the placebo
group. Liraglutide-treated subjects had
superior glycemic control compared with
thoseintheplacebogroup(liraglutide1.2
mg/day vs. placebo: 0.9% [95% CI
1.1to0.8]andliraglutide1.8mg/day
vs. placebo: 1.1% [1.1 to 0.8]).
Within the ﬁrst 12 weeks of the study,
meanA1Cvaluesdecreasedfrombaseline
for the liraglutide-treated groups and
thereafter remained steady throughout
the trial (Fig. 1A).
A logistic regression analysis demon-
stratedthatasigniﬁcantlygreaterpercent-
age of subjects in both of the liraglutide
groups achieved the ADA and AACE/IDF
A1C goals compared with placebo (P 
0.0001 for all comparisons of liraglutide
to placebo for both A1C goals) (Fig. 1B).
Attheendofthestudy,57.5and53.7%of
subjects in the 1.2 and 1.8 mg liraglutide/
day groups, respectively, had an A1C
7%, compared with 28.1% in the pla-
cebogroup,with37.3and36.2%,respec-
tively, reaching 6.5% compared with
14.4% with placebo.
FPG values decreased within 2 weeks
of randomization with liraglutide, re-
maining relatively stable thereafter, while
with placebo, smaller decreases occurred
(Fig. 1C). End-of-study FPG values were
139  49 mg/dl (7.7  2.7 mmol/l),
137  41 mg/dl (7.6  2.3 mmol/l), and
17154mg/dl(9.53.0mmol/l)inthe
1.2 and 1.8 mg liraglutide/day and pla-
cebo groups, respectively. The decreases
in FPG from baseline for the liraglutide
groups (40 mg/dl [2.2 mmol/l] and
44mg/dl[2.4mmol/l]for1.2and1.8
mg liraglutide/day groups, respectively)
were signiﬁcantly greater than the de-
creaseobservedintheplacebogroup(8
mg/dl [0.4 mmol/l], P  0.0001).
Mean 90-min PPG (mean of three
meals), from self-monitored seven-point
plasma glucose measurements at the end
of the study, decreased from baseline in
all treatment groups by 47 mg/dl (2.6
mmol/l) for 1.2 mg liraglutide/day, 49
mg/dl(2.7mmol/l)for1.8mgliraglutide/
day, and 14 mg/dl (0.8 mmol/l) for pla-
cebo (P  0.001 comparisons of all
liraglutide groups to placebo). The post-
prandial increment (postmeal value mi-
nus premeal) was signiﬁcantly reduced
over breakfast with liraglutide treatment
(16, 14, and 5 mg/dl [0.9, 0.8,
0.3 mmol/l], respectively; P  0.05 for
both liraglutide treatment groups vs. pla-
cebo) but not for lunch and dinner.
Mean change in body weight over
time is shown in Fig. 1D. Weight loss was
observed in the liraglutide-treated groups
([meansSE]1.00.3and2.00.3kg
from baseline for 1.2 and 1.8 mg lira-
glutide/day groups, respectively) and was
signiﬁcantly different (P  0.0001) from
the weight gain in the placebo group
Table 1—Characteristics of randomized population and subject disposition
1.2 mg Liraglutide 1.8 mg Liraglutide Placebo
Sex (%) (men/women) 57/43 51/49 62/38
Age (years) 55  10 55  11 55  10
Race (%) (C/B/A/I/O) 81/15/1/1/2 83/10/3/1/3 84/10/2/1/3
Ethnicity (Hispanic or Latino/not) 13/87 16/84 16/84
BMI (kg/m
2) 33.2  5.4 33.5  5.1 33.9  5.2
Duration of diabetes (years) 9  69  69  6
Prestudy OAD treatment
Monotherapy 29 (16) 29 (16) 32 (18)
Combination therapy 149 (84) 149 (84) 145 (82)
A1C (%) 8.5  1.2 8.6  1.2 8.4  1.2
FPG mg/dl (mmol/l) 182  43 (10.1  2.4) 185  43 (10.3  2.4) 180  47 (10.0  2.6)
SBP (mmHg) 129  14.8 126  14.2 128  14.5
DBP (mmHg) 75.8  9.0 75.2  8.4 76.2  9.2
Total cholesterol (mmol/l) 5.01  1.33 5.17  1.43 4.99  1.34
LDL cholesterol (mmol/l) 2.82  0.95 2.96  1.08 2.77  0.95
VLDL cholesterol (mmol/l) 0.74  0.38 0.76  0.38 0.71  0.36
HDL cholesterol (mmol/l) 1.26  0.32 1.27  0.31 1.25  0.28
Triglycerides (mmol/l) 2.41  2.24 2.39  1.88 2.74  2.80
Free fatty acids (mmol/l) 0.51  0.22 0.55  0.27 0.52  0.34
Randomized 178 178 177
Completers 153 (86) 133 (75) 121 (68)
Withdrawals 25 (14) 45 (25) 56 (32)
Adverse events* 11 (6) 27 (15) 6 (3)
Nausea/vomiting/diarrhea 5 (3) 19 (11) 0
Ineffective therapy 3 (2) 3 (2) 29 (16)
Noncompliance 4 (2) 4 (2) 5 (3)
Other 7 (4) 11 (6) 16 (9)
DataaremeansSDorn(%)unlessotherwiseindicated.*Theadverseeventsrowincludesnausea/vomiting/diarrhea.A,Asian;B,black;C,Caucasian;I,American
Indian; O, other.
LEAD-4 study
1226 DIABETES CARE, VOLUME 32, NUMBER 7, JULY 2009 care.diabetesjournals.org(0.6  0.3 kg). The weight loss in the 1.8
mg liraglutide/day group was signiﬁ-
cantly greater than the 1.2 mg liraglutide/
day group (P 	 0.011).
The 1.2 and 1.8 mg liraglutide/day
groupshadsigniﬁcantreductionsinmean
SBP compared with the placebo group
(Table2)(Fig.1E)(placebo-correcteddif-
ference: 1.2 mg liraglutide/day: 5.6
mmHg, P  0.0001; 1.8 mg liraglutide/
day: 4.5mmHg, P 	 0.0009). There
were no signiﬁcant differences between
treatment groups in diastolic blood pres-
sure (DBP). Minor, but statistically signif-
icant, increases in pulse rate were
observed in the liraglutide-treated groups
versus placebo (2 and 3 bpm for 1.2 mg
(P 	 0.0071) and 1.8 mg liraglutide (P 	
0.0001), respectively) with a decrease of
0.5 bpm for placebo. Changes in lipids
from baseline are presented in Table 2
showing that free fatty acid values de-
creasedwithliraglutidetreatmentascom-
pared with an increase with placebo, and
LDL cholesterol and triglycerides de-
creased signiﬁcantly more in the 1.2 mg
liraglutide group than in the placebo
group.
The decreases in the proinsulin-to-
insulinratiofrombaseline(baselineof0.4
across all groups) for the liraglutide
groups were signiﬁcant (P  0.05) com-
pared with the placebo group, which in-
creased from baseline (Table 2). The
increase in C-peptide was signiﬁcantly
greater in the liraglutide groups (131 and
Figure 1—A: A1C over time for the study population. B: Percentage of subjects achieving ADA and AACE/IDF A1C goals at the end of the study. C:
FPGvaluesovertime.D:Changeinbodyweightovertime.E:SBPovertime.F:Percentageofsubjectswithnauseabyweek.Dataareintenttotreat,
last observation carried forward for all postbaseline values, with the exception of F, which is data from the safety analysis set. Error bars shown in
A, C, D, and E are 2 
 SE. **P 	 0.0009; ***P  0.0001.
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respectively) compared with an increase
of 51 pmol/l for placebo (P  0.05 for
comparison of both liraglutide groups to
placebo). Both liraglutide treatment
groups had signiﬁcant improvements (in-
crease of 27 absolute percentage points)
in HOMA-B for both groups from base-
line values of 34 to 37%, respectively,
compared with an improvement in the pla-
cebo group of 6 absolute percentage points
from a baseline of 40% (P  0.0001 for
both groups vs. placebo). Insulin resistance
(measuredbyHOMA-IR)wasreducedinall
three treatment groups but was not signiﬁ-
cantly different between groups. No signif-
icant differences in the change-from-
baseline of HOMA-IR and fasting insulin
and glucagon values were observed be-
tweeneitheroftheliraglutidegroupsversus
the placebo group (Table 2).
Safety
Gastrointestinal disorders (including
nausea, vomiting, and diarrhea) were the
most frequently reported adverse events
in the liraglutide groups and were re-
ported by 45, 56, and 19% of the subjects
in the 1.2 and 1.8 mg liraglutide and pla-
cebogroups,respectively.Oneepisodeor
more of nausea was experienced by 29
and40%inthe1.2and1.8mgliraglutide
groups, respectively, and vomiting was
experienced by 7 and 17%, respectively.
The majority of nausea was transient, as it
occurred in the ﬁrst 4 weeks of liraglutide
treatment (216 events in weeks 1–4 vs.
65 events in weeks 4–26) (Fig. 1F). Dur-
ing the ﬁrst 8 weeks of treatment, 71–
84% of subjects in the liraglutide groups
and 98% of subjects in the placebo group
reported 7 days of nausea. Peripheral
edemawasreportedby5.1,1.7,and8.0%
in the 1.2 mg liraglutide, 1.8 mg lira-
glutide,andplacebogroups,respectively.
The percentages of subjects with-
drawn because of adverse events were
greater in the liraglutide groups than in
the placebo group (Table 1). Nausea,
vomiting, and/or diarrhea were the gas-
trointestinal events that lead to the with-
drawalofﬁvesubjectstreatedwith1.2mg
liraglutide and 19 subjects treated with
1.8 mg liraglutide (Table 1). Most gastro-
intestinal adverse events resulting in
withdrawal occurred during the ﬁrst
monthoftherapy.Therewerenoepisodes
of pancreatitis, and no deaths occurred.
Serious adverse events were infrequent (8
subjects [8 total events] for 1.2 mg lira-
glutide, 7 subjects [10 events] for 1.8 mg
liraglutide,and12subjects[13events]for
placebo).
Minor hypoglycemia occurred at low
incidence (9.0, 7.9, and 5.1% of subjects)
resulting in a low rate of reported minor
hypoglycemia (0.4. 0.6, and 0.2 events
per year) for the 1.2 mg liraglutide, 1.8 mg
liraglutide, and placebo groups, respec-
tively. The rate of minor hypoglycemia for
the 1.8 mg liraglutide group was signiﬁ-
cantlyhigherthanplacebo(P	0.004).No
major hypoglycemic event was reported.
No clinically relevant between-
treatment differences were observed in
physicalexaminationﬁndings,laboratory
analyses (hematology and biochemistry
analyses), electrocardiogram, or ophthal-
moscopy. There was no signiﬁcant treat-
ment effect with 1.8 mg liraglutide versus
placebo on calcitonin. Geometric mean–
estimated repeated-measurement analy-
sis showed calcitonin levels of 0.89, 0.83,
and 0.75 ng/l for 1.2 mg liraglutide, 1.8
mg liraglutide, and placebo, respectively,
at the end of the study (all values within
thenormalrange).Therewasasigniﬁcant
increase for the 1.2 mg liraglutide group
versus placebo group (P 	 0.022) but no
signiﬁcant difference with the 1.8 mg li-
raglutide group. No difference in cardio-
vascular adverse events was reported
between the liraglutide groups and pla-
cebo (ﬁve events [ﬁve subjects] with lira-
glutide 1.2, three events [three subjects]
with liraglutide 1.8, and four events [four
subjects] with placebo). There were 4.1
and 6.7% of subjects treated with 1.2 and
1.8 mg liraglutide and positive for lira-
glutide antibodies at the end of the study
(versusnonewithplacebo).Subjectswith
antibodies did not have an attenuated
A1C response.
CONCLUSIONS — Liraglutide ther-
apy in combination with metformin and
TZD provided signiﬁcant decreases in
A1C, FPG, and PPG with weight loss; de-
creases in SBP; and a low rate of minor
hypoglycemia. In addition, there were in-
dications of improvement in -cell func-
Table 2—Other end points of interest/metabolic intermediates change from baseline to end of study
Liraglutide 1.2 mg Liraglutide 1.8 mg Placebo
Blood pressure (mmHg)
SBP 6.7  1.1* 5.6  1.1* 1.1  1.2
DBP 2.3  0.7 1.9  0.7 0.8  0.7
-Cell function
Insulin (pmol/l) 6.0  5.8 5.6  5.5 6.8  6.0
C-peptide (pmol/l) 131  32* 144  31* 51  34
Proinsulin-to-insulin ratio 0.029  0.026* 0.085  0.26* 0.036  0.029
-Cell function (%) (HOMA-B) 27  4.4* 27  4.2* 6  4.5
Insulin resistance (HOMA-IR) 0.6  0.3 0.7  0.3 0.3  0.3
Proinsulin–to–C-peptide ratio 0.007  0.001* 0.008  0.001* 0.002  0.001
Fasting glucagon (pg/ml) 5.9  2.9 6.7  2.8 0.4  3.0
Lipids
Total cholesterol (mmol/l) 0.21  0.9 0.20  0.09 0.02  0.10
LDL cholesterol (mmol/l) 0.28  0.07* 0.23  0.07 0.10  0.07
VLDL cholesterol (mmol/l) 0.12  0.03 0.10  0.03 0.11  0.03
HDL cholesterol (mmol/l) 0.03  0.02 0.04  0.02 0.03  0.02
Triglycerides (mmol/l) 0.38  0.10* 0.32  0.10 0.13  0.11
Free fatty acids (mmol/l) 0.03  0.02* 0.05  0.02* 0.02  0.02
Data are means  SE, unless otherwise noted. *P  0.05 vs. placebo.
LEAD-4 study
1228 DIABETES CARE, VOLUME 32, NUMBER 7, JULY 2009 care.diabetesjournals.orgtion with liraglutide treatment compared
with placebo. While improvement in
-cell function may have been a conse-
quence of improved glucose control, it
could well be a direct effect of liraglutide,
which is known to stimulate glucose-
dependent endogenous insulin secretion.
Gastrointestinal adverse events were re-
ported more frequently with liraglutide
treatment, with most of the events occur-
ring early in treatment. The glucose-
lowering effects of the two doses of
liraglutide were similar, although there
were signiﬁcantly more gastrointestinal
adverse events with the higher dose.
However, it is likely that there is signiﬁ-
cant individual variation in the develop-
ment of nausea and glycemic
effectiveness.
The underlying pathophysiology of
type 2 diabetes is complex and involves
three main factors: a relative decrease in
-cell insulin secretory function; in-
creased glucose production by the liver,
which is at least partially mediated by in-
appropriately increased glucagon levels;
and decreased glucose uptake by muscle.
The triple therapy of metformin, TZD,
and GLP-1 receptor agonists has the po-
tential of addressing all three underlying
abnormalities and results in improved
glycemic control, potential weight loss,
andimprovementsin-cellfunctionwith
minimal risk of hypoglycemia. The use of
this triple therapy has demonstrated the
largestdecreasesinA1CandSBPvaluesin
the LEAD program. It should be noted
that 50% of the subjects initiated TZD
treatment during the run-in period, and
doses of metformin and TZD were maxi-
mized during this period, which may ac-
count for the improvements observed in
the placebo arm of this study.
Exenatide, a commercially available
GLP-1receptoragonist,isasyntheticver-
sion of exendin-4. Unlike liraglutide,
which is dosed once daily independently
of meals, exenatide is dosed twice daily
within 60 min of breakfast and dinner
(14). The ﬁndings in this study support
the ﬁndings of a previous study (15) in
which 233 subjects inadequately con-
trolled with a stable dose of TZD (rosigli-
tazone 4 mg/day or pioglitazone 30
mg/day)withorwithoutmetformintreat-
ment (79% were treated with metformin)
were randomized to add exenatide treat-
ment (n 	 121) or placebo (n 	 112) for
16 weeks of treatment. At the end of the
study, A1C values decreased by 0.89%,
compared with a slight increase of 0.09%
in the placebo group (P  0.001). Body
weight decreased by 1.75 kg (vs. 0.24 kg
in the placebo group; P  0.001), and
other measurements of glycemic control
(FPG, mean SMPG, and mean postpran-
dial SMPG values) all showed signiﬁcant
improvement with exenatide treatment.
These studies support the effectiveness of
this type of diabetes regimen, particularly
as it is associated with modest weight loss
and low risk of hypoglycemia.
The very signiﬁcant change in SBP
observed in this study appears to be of
larger magnitude than that observed in
the other LEAD studies. TZD treatment is
associated with a modest reduction in
blood pressure but is also associated with
ﬂuid retention. There may be an interac-
tion between the cardiovascular effects of
liraglutideandTZD.Furtherstudywould
beofobviousinterest,particularlyifthere
was potential for long-term cardiovascu-
lar beneﬁt.
The speciﬁc mechanism(s) of SBP re-
duction and the slight increases in pulse
withliraglutideremaintobefurtherstud-
ied. Based on data with native GLP-1, it
could be speculated that the effect on SBP
relatestoreducedrenalsodiumreabsorp-
tion (16,17). Native GLP-1 has been
shown to improve endothelial function in
patients with type 2 diabetes and coronary
heart disease (18) and in vitro endothelial
cell models (19). The latter has also been
shown for liraglutide (20). Potentially, the
slight increases in pulse observed with lira-
glutide may be compensatory for the de-
creases in SBP.
Insummary,thisstudydemonstrated
that the triple combination of liraglutide,
metformin, and TZD is an effective and
safe treatment for patients with type 2
diabetes. This combination signiﬁcantly
improved glycemic control and other ef-
ﬁcacy parameters, in addition to resulting
in signiﬁcant weight loss and improved
blood pressure.
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